The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)

Cohort 1 (STRESS-LUNG-1): Inclusion Criteria: 1. Age ≥ 18 years; 2. Histologically confirmed diagnosis of NSCLC; 3. Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition; 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy ); 6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ; 7. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy; 8. Informed and agreed to participate in the study; Exclusion Criteria: 1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) gene and/or ROS proto-oncogene 1 (ROS1) fusion-positive; 2. Combined with other malignant tumors in the past 3 years; 3. Concurrent acute or chronic psychiatric disorders; 4. Current receiving anti-depressive or anti-anxiety therapy; 5. Previous treatment with other clinical drug trials; 6. Patients with symptomatic brain metastasis; 7. Can't cooperate with psychological scale assessment; Cohort 2 (STRESS-LUNG-2): 1. Age ≥ 18 years； 2. Pathologically diagnosed as small cell lung cancer； 3. Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition; 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy ); 6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ; 7. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy; 8. Informed and agreed to participate in the study; Exclusion Criteria: 1. Combined with other malignant tumors in the past 3 years; 2. Concurrent acute or chronic psychiatric disorders; 3. Current receiving anti-depressive or anti-anxiety therapy; 4. Previous treatment with other clinical drug trials; 5. Patients with symptomatic brain metastasis; 6. Can't cooperate with psychological scale assessment; Cohort 3 (STRESS-LUNG-3): 1. Age ≥18 years ； 2. Pathologically diagnosed as non-small cell lung cancer; 3. Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition; 4. At least one measurable lesion can be evaluated according to the RECIST 1.1 standard； 5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy ); 6. Receiving PD-1/PD-L1 inhibitors combined with chemotherapy as neoadjuvant therapy. 6\. Cardiopulmonary function can withstand surgery; 7. Informed and agreed to participate in the study; Exclusion Criteria: 1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) gene and/or ROS proto-oncogene 1 (ROS1) fusion-positive; 2. Combined with other malignant tumors in the past 3 years; 3. Concurrent acute or chronic psychiatric disorders; 4. Current receiving anti-depressive or anti-anxiety therapy; 5. Previous treatment with other clinical drug trials; 6. Can't cooperate with psychological scale assessment; Cohort 4 (STRESS-LUNG-4): 1. Age ≥18 years; 2. Pathologically diagnosed as non-small-cell lung cancer； 3. Pathologically stage conformed as early stage of IA-IIIA 4. Available for tumor tissue samples； 5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy ); 6. Receiving radical surgery; 7. Informed and agreed to participate in the study; Exclusion Criteria: 1. Combined with other malignant tumors in the past 3 years; 2. Concurrent acute or chronic psychiatric disorders; 3. Current receiving anti-depressive or anti-anxiety therapy; 4. Previous treatment with other clinical drug trials; 5. Can't cooperate with psychological scale assessment;